New combo therapy offers hope for hard-to-treat endometrial cancer
NCT ID NCT04486352
First seen Oct 31, 2025 · Last updated May 20, 2026 · Updated 29 times
Summary
This study tests whether combining targeted drugs with the immunotherapy atezolizumab can shrink tumors or slow cancer growth in people with recurrent or persistent endometrial cancer. About 148 participants whose cancer has returned after at least one prior treatment will be enrolled. Researchers use genetic screening to match each person to a treatment most likely to work for their specific tumor type.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Atlantic Health Systems/Morristown Medical Center
ACTIVE_NOT_RECRUITINGMorristown, New Jersey, 07960, United States
-
Baptist Memorial Hospital
WITHDRAWNMemphis, Tennessee, 38120, United States
-
City of Hope Comprehensive Cancer Center
ACTIVE_NOT_RECRUITINGDuarte, California, 91010, United States
-
Dana Farber Cancer Institute
ACTIVE_NOT_RECRUITINGBoston, Massachusetts, 02125, United States
-
Duke University Cancer Center
ACTIVE_NOT_RECRUITINGDurham, North Carolina, 27710, United States
-
Englewood Health
ACTIVE_NOT_RECRUITINGEnglewood, New Jersey, 07631, United States
-
Lifespan - Rhode Island Hospital
ACTIVE_NOT_RECRUITINGProvidence, Rhode Island, 02903, United States
-
Maine Medical Center
ACTIVE_NOT_RECRUITINGScarborough, Maine, 04074, United States
-
Medstar Georgetown Cancer Institute
ACTIVE_NOT_RECRUITINGWashington D.C., District of Columbia, 20007, United States
-
Mount Sinai Comprehensive Cancer Center
ACTIVE_NOT_RECRUITINGMiami Beach, Florida, 33140, United States
-
Nebraska Methodist Hospital
ACTIVE_NOT_RECRUITINGOmaha, Nebraska, 68114, United States
-
Providence Portland Cancer Institute
ACTIVE_NOT_RECRUITINGPortland, Oregon, 97213, United States
-
Roswell Park
ACTIVE_NOT_RECRUITINGBuffalo, New York, 14263, United States
-
UCSF Helen Diller Family Comprehensive Cancer Center
ACTIVE_NOT_RECRUITINGSan Francisco, California, 94143, United States
-
University of Chicago
ACTIVE_NOT_RECRUITINGChicago, Illinois, 60637, United States
-
University of Kansas Cancer Center
ACTIVE_NOT_RECRUITINGWestwood, Kansas, 66205, United States
-
University of Minnesota
ACTIVE_NOT_RECRUITINGMinneapolis, Minnesota, 55455, United States
-
University of Oklahoma Health Stephenson Cancer Center
RECRUITINGOklahoma City, Oklahoma, 73104, United States
Contact
Contact
-
University of Pittsburgh Medical Center
ACTIVE_NOT_RECRUITINGPittsburgh, Pennsylvania, 15261, United States
-
Washington University School of Medicine Siteman Cancer Center
WITHDRAWNSt Louis, Missouri, 63110, United States
-
Weill Cornell Medicine
ACTIVE_NOT_RECRUITINGNew York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.